Cutting Screen Use Boosts Mental Health in Children, Teens
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 24, 2024 -- Short-term reduction in leisure-time screen media use within families positively affects psychological symptoms in children and adolescents, according to a study published online July 12 in JAMA Network Open.
Jesper Schmidt-Persson, Ph.D., from the Centre of Research in Childhood Health at the University of Southern Denmark in Odense, and colleagues investigated the effects of a two-week screen media reduction intervention on children's and adolescents' mental health. Analysis included 181 children and adolescents from 89 participating families.
The researchers found that there was a statistically significant mean difference in the total difficulties score, favoring the screen media reduction intervention (−1.67; Cohen d, 0.53). The greatest benefits were seen for internalizing symptoms (emotional symptoms and peer problems; between-group mean difference, −1.03) and prosocial behavior (between-group mean difference, 0.84).
"Future research should explore the potential differential effects of various types of screen media use and look deeper into whether collective family participation in such interventions is a pivotal component for observed benefits," the authors write. "Moreover, more research is needed to confirm whether these effects are sustainable in the long term."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-25 03:15
Read more
- Expanded Admission Screening Protocol for Candida Auris Beneficial
- Exercise Cuts Dependence in Those With Alcohol Use Disorder
- 2011 to 2022 Saw Increase in Autism Diagnoses Among Children, Adults
- Muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
- LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
- Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions